The 21 references in paper H. Rafrafi ., A. Rumyantsev Sh., Х. Рафрафи ., А. Румянцев Ш. (2015) “СТАТУС ВИТАМИНА D И СОСТОЯНИЕ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК С5Д СТАДИИ // VITAMIN D STATE AND CARDIOVASCULAR SYSTEM IN PATIENTS WITH CHRONIC KIDNEY DISEASE S5D STADE” / spz:neicon:nefr:y:2015:i:4:p:51-54

1
Cauley JA, Lacroix AZ, Wu L et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med.
(check this in PDF content)
2
08;149(4):242-250 2. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res. 2009;29(9):3687-3698
(check this in PDF content)
3
Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266281
(check this in PDF content)
4
Perna L, Schöttker B, Holleczek B, Brenner H. Serum 25-hydroxyvitamin D and incidence of fatal and nonfatal cardiovascular events: a prospective study with repeated measurements. J Clin Endocrinol Metab. 2013;98(12):4908-4915
(check this in PDF content)
5
Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int2005;68:1840-1848
(check this in PDF content)
6
Covic A, Kanbay M, Voroneanu L et al. Vascular calcification in chronic kidney disease. Clin Sci (Lond). 2010; 119(3):111-121
(check this in PDF content)
7
Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011;7(3):145-154
(check this in PDF content)
8
Волков ММ, Смирнов АВ, Добронравов ВА и др. Статус витамина D у пациентов с хронической болезнью почек и его связь с сердечно-сосудистой патологией. 2009; 13(2): 60-64
(check this in PDF content)
9
Mizobuchi M, Ogata H, Koiwa F et al. Vitamin D and vascular calcification in chronic kidney disease. Bone. 2009;45 Suppl 1:S26-29
(check this in PDF content)
10
Jean G, Terrat JC, Vanel T et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008;110:c58-c65
(check this in PDF content)
11
Hewitt NA, O’Connor AA, O’Shaughnessy DV, Elder GJ. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(7):1143-1149
(check this in PDF content)
12
Krause R. Vitamin D and UV exposure in chronic kidney disease. Dermatoendocrinol. 2013;5(1):109-116
(check this in PDF content)
13
Collins AJ, Foley RN, Herzog C, et al. USRDS 2012 Annual Data Report. Am J Kidney Dis. 2013;61(1) Suppl 1:e1–e421
(check this in PDF content)
14
Herzog C.A., Asinger R.W., Berger A.K.Berger et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6):572-586
(check this in PDF content)
15
Tangri N, Wagner M, Griffith JL et al. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis. 2011;57(3):415-421
(check this in PDF content)
16
Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):512-518
(check this in PDF content)
17
Lucchi L, Carboni C, Stipo L, et al. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. Artif Organs. 2011;35(12):1186-1193]
(check this in PDF content)
18
Добронравов В.А., Богданова E.О. Патогенез нарушений обмена фосфатов при хронической болезни почек: все ли так ясно, как кажется? Нефрология 2014 18(2): 42-46
(check this in PDF content)
19
Gutiérrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the “trade-off” hypothesis. Clin J Am Soc Nephrol. 2010 Sep;5(9):1710-1716
(check this in PDF content)
20
Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMTDDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60(6):461-465
(check this in PDF content)
21
Franceschelli S, Ferrone A, Pesce M et al. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci. 2013;14(12):24412-2421 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)